Clinical Trials Logo

HIV-1 Infection clinical trials

View clinical trials related to HIV-1 Infection.

Filter by:

NCT ID: NCT03580668 Not yet recruiting - HIV-1-infection Clinical Trials

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide

BIC-STaR
Start date: August 2018
Phase:
Study type: Observational

The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA <50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).

NCT ID: NCT03579381 Recruiting - HIV-1-infection Clinical Trials

Specimen Repository for HIV Immunopathogenesis

Start date: July 31, 2017
Phase:
Study type: Observational

Specimen Repository for HIV Immunopathogenesis Studies

NCT ID: NCT03570918 Not yet recruiting - HIV-1-infection Clinical Trials

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

Start date: June 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).

NCT ID: NCT03567304 Recruiting - HIV-1-infection Clinical Trials

Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

Start date: June 2018
Phase: Phase 4
Study type: Interventional

People living with HIV in the era of antiretroviral therapy (ART) continue to suffer high rates of neurocognitive disorder. This is a randomized control trial aiming to evaluate improvement of neurocognitive function after switching efavirenz (EFV) to rilpivirine (RPV). EFV based regimen is currently the first line ART in Thailand. There are several reports suggested that HIV-infected patients who took EFV based regimen had poorer neurocognitive function compared to the comparator. RPV, another first line regimen, has been known to have less neuropsychiatric side effects. We hypothesized that switching EFV to RPV could improve neurocognitive function.

NCT ID: NCT03552536 Not yet recruiting - HIV-1 Infection Clinical Trials

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

Start date: July 25, 2018
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-retroviral therapy (ART) activity of the tenofovir prodrug, MK-8583 monotherapy in ART-naïve, HIV-1 infected participants. The primary hypothesis is that at a dose that is sufficiently safe and generally well tolerated, MK-8583 has superior anti-retroviral activity compared to historical placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) (log10 copies/mL) at 168 hours post-dose.

NCT ID: NCT03549689 Not yet recruiting - HIV/AIDS Clinical Trials

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

ReNew
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, randomized pilot study to assess the effect on bone mineral density (BMD) of a switch from a tenofovir alafenamide-containing antiretroviral regimen to dolutegravir/lamivudine vs. a continuation of the tenofovir alafenamide-containing regimen.

NCT ID: NCT03549312 Recruiting - Clinical trials for Hepatitis C, Chronic

Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone

Start date: February 1, 2018
Phase: Phase 4
Study type: Interventional

The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone who are stably suppressed on current antiretroviral therapy to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF, Genvoya™) for 12 weeks followed immediately by 12 weeks of HCV antiviral therapy with sofosbuvir/velpatasvir (SOF/VEL, Epclusa™).

NCT ID: NCT03539224 Recruiting - HIV-1-infection Clinical Trials

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

Start date: November 2, 2017
Phase: Phase 2
Study type: Interventional

Phase IIa, open clinical trial, pilot, single arm and proof of concept.

NCT ID: NCT03536234 Recruiting - HIV-1-infection Clinical Trials

Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

Start date: May 2018
Phase: Phase 2
Study type: Interventional

An open, randomised, parallel arm phase IIa study. 52 HIV-1 infected patients will be randomised (in a 1:1 ratio) to either an active group or a control group. The active group will receive the GnRH analogue triptorelin depot monthly at baseline, week 4 and week 8. Patients in the active group and in the control group will continue their triple combination antiretroviral therapy (ART) during the study without changes; unless there is rationale for change on medical ground. In order to prevent the negative effects of a low testosterone level, patients in the active group will be offered to receive a single intramuscular depot injection of testosterone approximately 7 days after triptorelin treatment. This depot administration will keep the serum testosterone on a normal level until the next triptorelin dose. This will be repeated when triptorelin is administered at week 4 and week 8. Total study period is 24 weeks.

NCT ID: NCT03532425 Not yet recruiting - HIV-1-infection Clinical Trials

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Start date: July 2018
Phase: Phase 4
Study type: Interventional

Atripla (ATP: FTC/TDF/EFV) was the first single pill treatment for HIV and was the most prescribed first-line treatment from approximately 2008 to 2013 for people infected with HIV. However, ATP has not been recommended as a "preferred" treatment for HIV since 2015, due to there now being single pill treatments that work better. There are a lot of people who are still taking ATP and it is working for them. However, it has the potential to cause serious side effects (chronic kidney disease and fractures and serious neurological effects). These side effects are caused by components in ATP (namely the TDF and EFV parts). Also, the efavirenz (EFV) component is not compatible for treatment of Hepatitis C (HCV) - which is often also seen in people who have HIV. For these reasons, there is a need to find a better alternative treatment for these people currently being treated with ATP. B/F/TAF (bictegravir/FTC/TAF) is an investigational single pill drug treatment drug that contains neither TDF nor EFV. This study is looking at whether changing people to this new drug treatment will continue to suppress their HIV and have fewer side effects.